IL162431A0 - Corticotropin releasing factor 2 receptor agonists - Google Patents

Corticotropin releasing factor 2 receptor agonists

Info

Publication number
IL162431A0
IL162431A0 IL16243103A IL16243103A IL162431A0 IL 162431 A0 IL162431 A0 IL 162431A0 IL 16243103 A IL16243103 A IL 16243103A IL 16243103 A IL16243103 A IL 16243103A IL 162431 A0 IL162431 A0 IL 162431A0
Authority
IL
Israel
Prior art keywords
receptor agonists
releasing factor
corticotropin releasing
corticotropin
factor
Prior art date
Application number
IL16243103A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of IL162431A0 publication Critical patent/IL162431A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16243103A 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists IL162431A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19
PCT/US2003/001461 WO2003062269A2 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists

Publications (1)

Publication Number Publication Date
IL162431A0 true IL162431A0 (en) 2005-11-20

Family

ID=27617822

Family Applications (5)

Application Number Title Priority Date Filing Date
IL16243103A IL162431A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists
IL15252903A IL162529A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists
IL16253003A IL162530A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists
IL196384A IL196384A0 (en) 2002-01-16 2009-01-07 Corticotropin releasing factor 2 receptor agonists
IL197774A IL197774A0 (en) 2002-01-16 2009-03-24 Corticotropin releasing factor 2 receptor agonists

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL15252903A IL162529A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor 2 receptor agonists
IL16253003A IL162530A0 (en) 2002-01-16 2003-01-16 Corticotropin releasing factor receptor 2 agonists
IL196384A IL196384A0 (en) 2002-01-16 2009-01-07 Corticotropin releasing factor 2 receptor agonists
IL197774A IL197774A0 (en) 2002-01-16 2009-03-24 Corticotropin releasing factor 2 receptor agonists

Country Status (30)

Country Link
US (7) US6936585B2 (xx)
EP (4) EP1465921B1 (xx)
JP (3) JP4508649B2 (xx)
KR (3) KR100758857B1 (xx)
CN (3) CN100391972C (xx)
AR (3) AR038144A1 (xx)
AT (4) ATE334147T1 (xx)
AU (2) AU2003205197B2 (xx)
BR (3) BR0306878A (xx)
CA (3) CA2470743C (xx)
CY (1) CY1106133T1 (xx)
DE (4) DE60321730D1 (xx)
DK (2) DK1465921T3 (xx)
ES (4) ES2299701T3 (xx)
HK (1) HK1078095A1 (xx)
IL (5) IL162431A0 (xx)
MA (3) MA27591A1 (xx)
MX (3) MXPA04006885A (xx)
MY (1) MY140306A (xx)
NO (3) NO20043366L (xx)
NZ (3) NZ533599A (xx)
PE (3) PE20030974A1 (xx)
PL (3) PL373529A1 (xx)
PT (2) PT1465921E (xx)
RU (1) RU2294333C2 (xx)
SA (3) SA03230565B1 (xx)
SI (1) SI1465921T1 (xx)
TW (3) TW200302278A (xx)
WO (3) WO2003062269A2 (xx)
ZA (1) ZA200404995B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
BRPI0609460A2 (pt) * 2005-03-30 2010-04-13 Novartis Vaccines & Diagnostics Inc haemophilus influenzae tipo b
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
WO2009033773A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
AU2008297874A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of secretin and optionally urodilatin as therapeutic agents
US10040838B2 (en) * 2008-11-04 2018-08-07 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
MX2012005262A (es) * 2009-11-04 2012-09-28 Janssen Pharmaceutica Nv Metodo para tratar la insuficiencia cardiaca con petidos tipo estrescopina.
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
WO2013123094A2 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
MX2019004401A (es) * 2016-10-20 2019-09-26 Cortene Inc Metodos de tratamiento y enfermedades resultantes de una respuesta de tension mal adaptada.
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
AU2001284683B2 (en) 2000-08-04 2006-04-27 Research Development Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
PE20030849A1 (es) 2003-12-01
JP4489434B2 (ja) 2010-06-23
KR100758857B1 (ko) 2007-09-14
DE60313845D1 (de) 2007-06-28
MA27591A1 (fr) 2005-11-01
NZ533599A (en) 2007-03-30
JP2005525101A (ja) 2005-08-25
NZ533600A (en) 2007-02-23
PE20030974A1 (es) 2003-12-26
CN100391972C (zh) 2008-06-04
MY140306A (en) 2009-12-31
DK1465923T3 (da) 2007-07-02
US20030148956A1 (en) 2003-08-07
AU2003205197B2 (en) 2006-03-02
ATE398632T1 (de) 2008-07-15
CN1617886A (zh) 2005-05-18
US7192924B2 (en) 2007-03-20
BR0306838A (pt) 2005-04-05
CN1617887A (zh) 2005-05-18
DK1465921T3 (da) 2006-11-27
KR100735586B1 (ko) 2007-07-04
NO20043371L (no) 2004-10-06
ATE383372T1 (de) 2008-01-15
PT1465923E (pt) 2007-08-06
TWI300442B (en) 2008-09-01
KR20040082389A (ko) 2004-09-24
AU2003237419B2 (en) 2006-04-13
SA03230565B1 (ar) 2006-10-31
SA03230564A (ar) 2005-12-03
DE60321730D1 (de) 2008-07-31
US7192923B2 (en) 2007-03-20
US7462597B2 (en) 2008-12-09
US20030148957A1 (en) 2003-08-07
CN100475844C (zh) 2009-04-08
US7632933B2 (en) 2009-12-15
CA2470656A1 (en) 2003-07-31
ATE334147T1 (de) 2006-08-15
NO20043396L (no) 2004-10-06
US6936585B2 (en) 2005-08-30
EP1465921B1 (en) 2006-07-26
MA27590A1 (fr) 2005-11-01
ES2269976T3 (es) 2007-04-01
PL373139A1 (en) 2005-08-22
EP1724283A2 (en) 2006-11-22
PL371364A1 (en) 2005-06-13
MXPA04006884A (es) 2004-12-06
MXPA04006885A (es) 2004-12-06
WO2003062277A1 (en) 2003-07-31
JP2005522191A (ja) 2005-07-28
MXPA04006883A (es) 2004-12-06
RU2294333C2 (ru) 2007-02-27
WO2003062269A3 (en) 2003-11-06
ATE362488T1 (de) 2007-06-15
ES2287484T3 (es) 2007-12-16
DE60313845T2 (de) 2008-01-31
EP1724283B1 (en) 2008-06-18
TW200302278A (en) 2003-08-01
US7608701B2 (en) 2009-10-27
NZ533598A (en) 2007-03-30
ES2309909T3 (es) 2008-12-16
TW200302277A (en) 2003-08-01
US20060025339A1 (en) 2006-02-02
TW200302276A (en) 2003-08-01
EP1465923A1 (en) 2004-10-13
WO2003062268A3 (en) 2003-11-27
EP1465922A2 (en) 2004-10-13
IL196384A0 (en) 2011-07-31
WO2003062268A2 (en) 2003-07-31
SI1465921T1 (sl) 2006-10-31
SA03230564B1 (ar) 2006-10-31
BR0306826A (pt) 2005-09-06
CA2470731C (en) 2011-06-21
JP2005521387A (ja) 2005-07-21
EP1465921A2 (en) 2004-10-13
RU2004124847A (ru) 2005-04-20
AR038143A1 (es) 2004-12-29
DE60318547T2 (de) 2008-12-24
AR038144A1 (es) 2004-12-29
IL162530A0 (en) 2005-11-20
US20030148958A1 (en) 2003-08-07
KR20040082390A (ko) 2004-09-24
KR20040082392A (ko) 2004-09-24
US20090124793A1 (en) 2009-05-14
SA03230565A (ar) 2005-12-03
US20080004435A1 (en) 2008-01-03
ZA200404995B (en) 2005-06-29
CA2470743C (en) 2011-12-13
HK1078095A1 (en) 2006-03-03
PT1465921E (pt) 2006-12-29
CA2470656C (en) 2011-06-28
US20100197579A1 (en) 2010-08-05
CA2470731A1 (en) 2003-07-31
PL373529A1 (en) 2005-09-05
NO20043366L (no) 2004-10-06
DE60307044T2 (de) 2007-02-15
CN1617885A (zh) 2005-05-18
DE60307044D1 (de) 2006-09-07
WO2003062269A2 (en) 2003-07-31
PE20030747A1 (es) 2003-10-23
ES2299701T3 (es) 2008-06-01
BR0306878A (pt) 2004-10-26
IL197774A0 (en) 2009-12-24
EP1465923B1 (en) 2007-05-16
JP4508649B2 (ja) 2010-07-21
AR038142A1 (es) 2004-12-29
EP1724283A3 (en) 2007-04-11
KR100758858B1 (ko) 2007-09-14
JP4508648B2 (ja) 2010-07-21
US7897731B2 (en) 2011-03-01
CA2470743A1 (en) 2003-07-31
DE60318547D1 (de) 2008-02-21
IL162529A0 (en) 2005-11-20
CY1106133T1 (el) 2011-06-08
EP1465922B1 (en) 2008-01-09
MA27592A1 (fr) 2005-11-01

Similar Documents

Publication Publication Date Title
IL197774A0 (en) Corticotropin releasing factor 2 receptor agonists
EP1482895A4 (en) AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
AP1916A (en) Purine compounds and use thereof as cannabinoid receptor ligands
IL150632A0 (en) Corticotropin releasing factor antagonists
EP1482896A4 (en) AMINOALKYLPHOSPHONATES AND ASSOCIATED COMPOUNDS AS EDG RECEPTOR AGONISTS
EP1559422A4 (en) CONTROLLER OF RECEIVER FUNCTION
HUP0401437A3 (en) Adenosine a3 receptor agonists
AU6497701A (en) Melanocortin receptor agonists
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
GB0226227D0 (en) Receptors
ZA200404994B (en) Corticotropin releasing factor 2 receptor agonists
SI1465923T1 (sl) Agonisti receptorja 2 faktorja sproščanja kortikotropina
GB0215389D0 (en) Receptor
AU2003300867A8 (en) Uses of the snorf207 receptor
GB0223399D0 (en) Receptors
AU2002302807A1 (en) Corticotropin releasing factor antagonists
GB0201849D0 (en) A�- adenosine receptor agonists
GB0201919D0 (en) A�-Adenosine receptor agonists
SI1558615T1 (sl) Purinske spojine in uporaba le-teh kot ligandov kanabinoidnega receptorja
GB0408398D0 (en) Leptin receptor agonists (3)
GB0408454D0 (en) Leptin receptor agonists (1)
GB0302925D0 (en) 4P re use 001
AU2003297644A8 (en) Uses of the snorf55 receptor